WO2025177214 - THERAPEUTIC METHODS
National phase entry is expected:
Publication Number
WO/2025/177214
Publication Date
28.08.2025
International Application No.
PCT/IB2025/051849
International Filing Date
20.02.2025
Title **
[English]
THERAPEUTIC METHODS
[French]
MÉTHODES THÉRAPEUTIQUES
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
ABIÁN, María Teresa Letosa
PEÑAFIEL, Marta Maria Benjumeda
FARAHMAND, Saman
PARASKEVOPOULOU, Maria D.
Priority Data
63/555,539
20.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3480 | |
| EPO | Filing, Examination, Granting | 26184 | |
| Japan | Filing, Examination, Granting | 3110 | |
| South Korea | Filing, Examination, Granting | 4009 | |
| USA | Filing, Examination, Granting | 15190 |
Total:
51,973
Contact Us
Abstract[English]
The invention provides methods related to combination therapies comprising an anti- α4β7 antibody, e.g., vedolizumab, and a JAK inhibitor for treating inflammatory bowel disease.[French]
L'invention concerne des méthodes associées à des polythérapies comprenant un anticorps anti-α4β7, par exemple, le vedolizumab, et un inhibiteur de JAK pour le traitement d'une maladie intestinale inflammatoire.